Technology evaluation: MRA, Chugai.
Article Details
- CitationCopy to clipboard
Ding C, Jones G
Technology evaluation: MRA, Chugai.
Curr Opin Mol Ther. 2003 Feb;5(1):64-9.
- PubMed ID
- 12669473 [ View in PubMed]
- Abstract
Chugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.
DrugBank Data that Cites this Article
- Drugs